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In February 2013, the Organ Procurement and Trans-
plantation Network mandated that transplant centers
perform screening of living kidney donors prior to
transplantation for Strongyloides, Trypanosoma cruzi
andWestNile virus (WNV) infection if the donor is from
an endemic area. However, specific guidelines for
screening were not provided, such as the optimal
testing modalities, timing of screening prior to dona-
tion and the appropriate selection of donors. In this
regard, the American Society of Transplantation Infec-
tious Diseases Community of Practice, together with
disease-specific experts, has developed this viewpoint
document to provide guidance for the testing of live
donors for Strongyloides, T. cruzi and WNV infection,
specifically identifying at-risk populations and testing
algorithms, including advantages, limitations and
interpretation of results.
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Introduction
Strongyloides, Trypanosoma cruzi and West Nile virus
(WNV) are important pathogens that have been transmitted
via deceased organ donors. Given the potential for
transmission to result from living donation, the Organ
Procurement and Transplantation Network (OPTN) man-
dated, effective February 2013, that transplant centers
must test for evidence of infection with Strongyloides,
T. cruzi and WNV if the potential live donor is from an
endemic area (1). However, the policy does not provide
specific guidance regarding implementation, including
appropriate selection of donors for testing, optimal testing
modalities and timing. Therefore, the American Society
of Transplantation Infectious Diseases Community of
Practice, in conjunction with disease-specific experts, has
developed this viewpoint to provide guidance related to
testing of live donors for these infections with a focus on
the identification of at-risk populations, advantages and
limitations of specific testing algorithms, and interpretation
of results.
Strongyloides
Infection with Strongyloides stercoralis occurs when
the larvae penetrate the skin of persons walking in soil
contaminated with feces and typically occurs in people
from rural agricultural areas, especially if poor sanitation
exists. Autoinfection is an important source of prolonged
carriage and adult worms can live for up to 5 years, allowing
for ongoing infection even when the donor is no longer
living in the endemic area. Consequently, individuals may
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remain chronically infected and able to transmit infection
throughout their lives via organ donation. Individuals
infected with Strongyloides are often asymptomatic;
symptomatic infection occurs more commonly in immuno-
compromised hosts. Manifestations may be variable and
involve the gastrointestinal and/or pulmonary tracts, sepsis
syndromes, gram-negative bloodstream infections, and/or
meningitis (especially with gram-negative organisms). The
most severe manifestation is hyperinfection syndrome (2).
The precise prevalence of chronic infection is unknown.
The disease occurs throughout the world and infection
rates are highest in tropical or subtropical regions,
exceeding 80% in some locations. In the United States,
rates as high as 3.8% have been measured in Appalachia
and southeastern states (3). The last community-based
survey was conducted in 1982, and current rates are
unknown.
Which living donor candidates should be screened
for Strongyloides?
Strongyloidiasis typically occurs only in the setting of
specific environmental exposures; thus, screening all
potential live donors is not indicated. Screening is justified
for the following potential organ donors:
 Persons who were born in or lived in tropical or
subtropical countries where sanitation conditions are
substandard. This includes candidates with prior military
service in endemic areas. Strongyloidiasis has occurred
in most countries with the exception of Canada, Japan
and Northern Europe.
 Persons with unexplained eosinophilia and travel to
endemic area.
 Those born in the United States who have significant
exposure to soil in Appalachia or the southeasternUnited
States.
 Persons reporting a prior history of Strongyloides
infection.
How should donor candidates be screened for
Strongyloides?
Strongyloides IgG antibody testing is readily available in
many reference labs (Table 1). Currently, these ELISA
assays (which correlate with antibody to filariform larvae)
are not specifically approved by the Food and Drug
Administration (FDA) for donor testing. Test sensitivities
vary and false-negative results have occurred, including in
early infection and immunocompromised hosts. Indirect
immunofluorescence assays have improved sensitivity;
however, they are generally only available through research
laboratories. There is no standard commercially available
confirmatory testing for antibody positive specimens; false-
positive tests are uncommon. Individuals with a history of
treatment for Strongyloides infection may have persistent
antibody; consequently, those donors should undergo
further evaluation by an expert in infectious diseases.
Serology is the preferred screening test for Strongyloides
infection, as the sensitivity of stool testing is limited and
multiple stool screening tests may be negative in asymp-
tomatic chronic infection. Fecal examination for Strong-
yloides larvae may sometimes identify additional infected
individuals who are newly infected and can be requested at
the time of the initial evaluation. Because the methodology
used to identify Strongyloides differs from that for routine
ova and parasite examinations, it is important to specify
the organism when ordering the test. Multiple stool
specimens should be obtained to increase the yield;
the optimal number is unknown but reports note that
seven consecutive daily specimens may increase the
sensitivity to nearly 100% (4). Given that transplant
candidates may share similar epidemiological risk factors
for Strongyloides infection, potential recipients with similar
geographic exposures should also be considered for
screening and treatment should be administered if found
to be positive.
Eosinophilia is commonly seen in patients with active
Strongyloides infection. Thus, those individuals with
potential environmental exposures and unexplained eosin-
ophilia should undergo serological testing and fecal
examination for Strongyloides. However, since eosinophilia
is not universally noted in patients with chronic strongyloi-
diasis, it should not be used as the only determinant
for which individuals are screened with serologic testing.
The optimal timing of live donor testing has not been
established. However, unless the donor will resume
residence in an environment where new exposures are
likely, it is reasonable to test at the time of donor
identification.
Table 1: Serological tests available for Strongyloides infection1
Test name Test format Sample type Available through
Strongyloides IgG antibody EIA Serum Focus Diagnostics, Inc.
Strongyloides antibody, IgG EIA Serum ARUP Labs, Salt Lake City, UT
Strongyloides IgG antibody EIA Serum Mayo Medical Laboratories
Strongyloides IgG antibody IVD-ELISA EIA Serum IVD Research, Carlsbad, CA
Strongyloides IgG antibody EIA Serum Quest Diagnostics Nichols Institute
1Serological testing also available via CDC.
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Can infected donors be considered for
transplantation?
Donor-derived strongyloidiasis has been rarely reported in
the setting of deceased kidney donation, typically related to
the use of donors from endemic areas (5). It has been
suggested that the risk of donor-derived strongyloidiasis is
enhanced due to predonation conditioning with high-dose
corticosteroids. Consequently, it is unclear if live donors
will pose the same risk for transmission as noted with
deceased donors. Nevertheless, given the availability of
effective treatment options for Strongyloides infection,
infected individuals can be considered for live donation.
Ideally, infected donors should be treated with a minimum
of two doses of ivermectin prior to donation (200mg/kg
orally daily on 2 consecutive days) (6). Because of the
potential for persistence of migrating larvae and eggs
in the tissues, some experts recommend repeating this
treatment 2 weeks later to cover an autoinfection cycle.
Following treatment, there is no need for follow-up
laboratory testing of the donor prior to donation for
confirmation of cure, unless re-exposure has occurred.
How should the recipients of Strongyloides-positive
donor organs be managed posttransplant?
If the donor is treated prior to donation, no specific
treatment or monitoring of the recipient is required as the
likelihood of transmission is probably extremely low.
If the donor cannot be treated prior to donation or receives
only a single course of treatment, then the recipient should
be treated with the same regimen as outlined for the donor
(considering two courses of two doses of ivermectin
separated by 2 weeks as the most conservative approach)
as soon as possible after the transplant has occurred (7).
There are no significant drug interactions and the medica-
tion is typically well tolerated with no requirement for
dose adjustment based on either renal or hepatic function.
All recipients of organs from donors with Strongyloides
infection should be monitored clinically; no additional
serological or microbiological studies are indicated in the
absence of symptoms. If recipients develop signs and
symptoms consistent with Strongyloides infection or
eosinophilia, expert consultation should be obtained.
Serological diagnosis is unreliable in patients receiving
immunosuppressive medications; therefore, appropriate
samples (e.g. stool, respiratory samples) should be
obtained for direct examination for Strongyloides larvae.
Because eosinophilia is not always present, its absence
cannot exclude the diagnosis. Recipients with posttrans-
plant Strongyloides infection should be treated with
ivermectin; the dose and duration may vary with the
specific clinical syndrome and expert consultation should
be solicited (7).
Chagas Disease
T. cruzi infection (the agent of Chagas disease) is most
commonly transmitted through contact with infected
triatomine ‘‘kissing’’ bugs, but transmission has also
been reported through blood transfusion, organ transplan-
tation and from mother to infant. Residents of poorly
constructed housing where these insects reside are at
greatest risk of acquiring infection. Endemic areas include
many parts of Mexico and most of Central and South
America (see Table 2). However, due to recent immigration
it is estimated that more than 300000 T. cruzi infected
people are living in the United States. In the United States,
32 organ transplant recipients from 14 T. cruzi seropositive
donors have been investigated: 2 of 15 (13%) kidney
recipients had donor-derived infection (8). A transmission
rate of 18.7%was observed in a case series fromArgentina
of T. cruzi seropositive kidney donors and T. cruzi
seronegative recipients (9). No live donor-derived T. cruzi
infection has been reported in the United States but this
has been described in Mexico and South America (8,9).
Clinical manifestations of donor-derived T. cruzi infection
can include fever, malaise, anorexia, hepatosplenomegaly
and acute myocarditis with a mean time to diagnosis of
infection of 8 weeks (range 3–29 weeks) (8).
Which living donor candidates should be screened
for Chagas disease?
T. cruzi can remain latent in humans for decades and be
transmitted by organ donation with severe consequences
to the recipient. Therefore, screening potentially infected
living donors is appropriate. Individuals reporting only brief
visits to endemic areas or residence confined to urban areas
are considered lower risk for T. cruzi infection and may not
need to be screened; however, these criteria have not been
fully evaluated.
Table 2: Countries with endemic Chagas disease1,2
Argentina
Belize
Bolivia
Brazil
Chile
Colombia
Costa Rica
Ecuador
El Salvador
French Guiana
Guatemala
Guyana
Honduras
Mexico
Nicaragua
Panama
Suriname
Paraguay
Peru
Uruguay
Venezuela
Adapted from: http://www.cdc.gov/parasites/cme/chagas/course.
html.
1See (1).
2A map of endemic areas for Trypanosoma cruzi infection is
available on the World Health Organization website.
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Donors who should be screened include:
 Those who were born in or lived in an endemic region
in Mexico, Central or South America (see Table 2).
 Children of women who lived in endemic regions and
whose T. cruzi infection status is positive or unknown.
 Persons who have received a blood transfusion in
endemic regions.
 Persons reporting a prior history of Chagas disease.
How should at-risk donor candidates be tested for
Chagas disease?
At the time of evaluation, potential living donors should be
tested for Chagas disease using serologic methods to
detect antibody (Table 3). Serology is preferred because
individuals with indeterminate chronic phase T. cruzi
infection have extremely low-level parasitemia, and there-
fore polymerase chain reaction (PCR), smears and cultures
have low sensitivity. Once infected, antibody levels are
usually detectable within 1 month and persist throughout
life.
Three FDA-cleared diagnostic tests for Chagas disease are
available for screening in the United States (Table 3). The
Ortho T. cruzi enzyme-linked immunoassay (EIA) test
system is used in blood donor screening and has been
approved for diagnostic testing aswell but is not available in
individual test kits; coordination with blood donor testing
centers would be required to utilize this test. The Hemagen
Chagas’ Kit (Hemagen Diagnostics, Inc., Columbia, MD)
and the Chagatest EIA Recombinante v. 3.0 (Wiener
Laboratories, Rosario, Argentina) are individual test kits
for patient testing and could be used to diagnose infection
in potential donors. Potential donors with any of the noted
epidemiologic risk factors for Chagas should undergo one
of the three available tests; notably performance does differ
among the available tests. If the initial screening test result
is positive, a second test utilizing a different antigen or
technique is recommended for serologic confirmation.
There is no gold standard for testing for T. cruzi and
discordant test results are an indication for further testing.
All live donors should be notified of their test results.
Consultation with infectious diseases experts is recom-
mended for evaluation of potential donors whose initial
screening test is positive for further testing recommenda-
tions, interpretation of test results and assessment of the
need for donor treatment.
Can infected donors be considered for
transplantation?
Available data indicate that the risk of transmission of
T. cruzi from a deceased kidney donor to an uninfected
organ recipient is 13–18% (8,10). The risk of transmission
from live kidney donors is unknown. Posttransplant
monitoring can be performed to identify subclinical infec-
tion and treatment can abort the development of clinical
disease following infection. Therefore, the authors agree
with recent guidelines considering kidney donation from
infected donors on an individual basis with consent of
the recipient (10). Potential recipients meeting criteria for
T. cruzi screening should also be tested regardless of the
donor’s T. cruzi status. It is possible that many potential
Table 3: Serological tests available for T. cruzi infection1
Test name, manufacturer Target antigen Test format Sample type FDA-cleared/approved use
Abbott Prism Chagas (T. cruzi
[E. coli, recombinant]
antigen),2 Abbot Laboratories,
Abbott Park, IL
Recombinant antigens ChLIA Serum/plasma Donor screening
ORTHO T. cruzi ELISA Test
System,3 Ortho-Clinical
Diagnostics, Inc., Raritan, NJ
Whole cell lysate EIA Serum/plasma Donor screening, individual
diagnosis
Chagatest ELISA recombinant
v.3.0,3 Wiener Laboratories
S.A.I.C., Rosario, Argentina
Recombinant
epimastigote and
trypomastigote
proteins
EIA Serum/plasma Diagnosis, NOT donor
screening test
Hemagen Chagas’ Kit,
Hemagen Diagnostics, Inc.,
Columbia, MD
Purified antigens from
cultured T. cruzi
EIA Serum Diagnosis, NOT donor
screening test
Abbott ESA Chagas Assay,
Abbott Laboratories, Abbott
Park, IL
4 T. cruzi recombinant
antigens (FP10, FP6,
FP3, TcF)
Enzyme
Strip Assay
Serum/plasma Supplemental test in donors
who test positive with
first-line assays, not
approved for individual
diagnosis
Adapted from http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicenseProducts.
1Serological testing also available via CDC.
2This test may only be available through local blood bank.
3Preferred tests for initial donor screening.
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living donors share risk factors with their designated
recipients; the risk of symptomatic disease when both
donor and recipient are T. cruzi positive is unknown.
Regardless, chronic recipient infection should be identified
pretransplant to direct monitoring for reactivation disease
after immunosuppression.
If transplantation from an infected donor is planned, given
the complexity of posttransplant management, the follow-
ing issues should be considered:
 Recipients should receive specific information regarding:
o The risk of transmission and the limited data regarding
this risk, especially pertaining to live donors.
o The posttransplant monitoring process.
o The potential toxicities associated with treatment for
Chagas disease.
o The need for participation in close monitoring of
therapeutic interventions in the event of infection,
since the medications available for treatment are not
FDA approved and are generally only provided through
specific protocols.
 Specific plans for posttransplant monitoring must be
in place at the time of transplantation. It is imperative to
consider the recipient’s access to testing andmonitoring
as geographic concerns may impact the ability to follow
the patient closely.
How should the recipients of T. cruzi positive donor
organs be managed posttransplant?
Following transplant, monitoring of recipients of kidneys
from T. cruzi positive organ donors should be coordinated
by local infectious disease experts and incorporate testing
at a reference lab (such as the Centers for Disease Control
and Prevention [CDC]). Serologic conversion may not occur
due to posttransplant immunosuppressive therapy. Moni-
toring can be accomplished by PCR testing of blood for
T. cruzi DNA and review of peripheral blood for parasitemia
weekly for 2 months posttransplant, every 2 weeks for
the third month, then monthly afterward for a period to
be determined by the specific clinical scenario (10). An
assessment of the organ recipient’s net state of immuno-
suppression should be made in the first months posttrans-
plant, and themonitoring interval adjusted accordingly. PCR
testing (currently available only at CDC) is more sensitive
than direct parasitologic diagnosis, and may be positive
days or weeks prior to the appearance of T. cruzi
trypomastigotes in the blood (10). Indirect methods of
parasite diagnosis such as hemoculturemay require weeks
to several months to obtain results. Additional testing is
recommended in the setting of intensified immunosup-
pression, unexplained febrile illness or infection symptoms,
or episodes of suspected graft rejection. The likelihood of
late reactivation of donor-derived infection is unknown.
Routine prophylaxis of the recipient of a T. cruzi positive
donor organ is not recommended (10–12). Treatment with
both benznidazole and nifurtimox is frequently complicated
by significant side effects and there is no clear treatment
end point to indicate when infection is definitively cured.
Consequently, even recipients of donors who had been
previously treated need to be monitored for posttransplant
parasitemia. Because neither benznidazole nor nifurtimox is
FDA approved or commercially available in the United
States, these medications must be obtained for patients
with confirmed T. cruzi infection through an investigational
new drug (IND) protocol directly from CDC or independent-
ly. For this reason, and because of the expertise of CDC
laboratories in expedited testing of high-risk organ recipi-
ents, early notification of CDC at the time of transplant is
advised. Ideally treatment should be initiated in those with
increasing reactivity in serial PCR as seropositivity occurs
later (8,13). In the United States, consultation about known
or suspected T. cruzi infections, confirmatory testing,
monitoring and treatment of transplant recipients should
be directed to the Division of Parasitic Diseases and
Malaria, CDC (Tel: 404-718-4745, parasites@cdc.gov, or
CDC Emergency Operations Center 770-488-7100). Treat-
ment of donor-derived infection requires close monitoring
for adverse effects, and the involvement of an infectious
diseases consultant is recommended.
West Nile Virus
WNV is a flavivirus that is transmitted by mosquitoes in an
enzootic cycle with birds. In the United States, WNV was
first noted in 1999 in the New York City area and has since
become endemic in widespread regions of the United
States (14). WNV infection is associated with a range of
clinical symptoms ranging from asymptomatic infection to
neuroinvasive disease. In the immunocompetent popula-
tion, neuroinvasive disease occurs in 1 in 150 infected
individuals and is manifested by altered mental status,
meningitis, encephalitis, flaccid paralysis and occasionally
death; these complications are estimated to occur in 1 in
40 transplant recipients infected by mosquito bites (15).
Transmission has also occurred via blood and deceased
organ donation with an incidence of neuroinvasive disease
ranging between 50%and 75% (16–18). Since 2002, donor-
derived transmission events associated with at least nine
donors infecting solid organ transplant recipients have been
reported (17–23). No transmissions have been reported via
live donor transplants thus far.
Which living donors should be screened for WNV?
Because WNV is seasonal throughout the United States,
year round screening of potential living donors is unlikely to
be cost-effective and may result in increased false-positive
results associated with testing low prevalence popula-
tions (24). As false-positive results may result in potential
organ loss or unnecessary delays in transplantation, timing
of testing is critical. Blood banks in the United States
screen year-round for WNV using nucleic acid amplification
testing (NAT) which identifies the presence of RNA. Due to
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limitations in reagent availability, personnel and other
logistical issues, blood donors are tested in minipools
(minipool-nucleic acid amplification test [MP-NAT]). Once
one or more minipools is positive by NAT, the blood bank
begins screening individual samples (individual donation-
nucleic acid amplification test [ID-NAT]) (25).
One potential strategy for determining when to begin
testing potential living donors for WNV would be to follow
when regional blood banks start performing ID-NAT
screening. This will allow for recognition of the onset of
WNV in the donor’s region of residence, travel or work
locations (26). This approach requires coordination with
blood banks. Further, blood banks vary in their criteria from
switching betweenminipool and individual NAT; there is no
national standard for blood banks on this issue. Conse-
quently, while basing testing of living donors on regional
blood banking WNV results may be cost-effective and
associated with the highest positive predictive value for
positive NATs, this approach may be impractical for some
transplant centers. Knowledge of epidemiologic data such
as the number of clinical cases or presence of positive bird
or mosquito pools in the donor’s areas of potential
exposures as reported by local health departments may
be useful to transplant centers assessing WNV risk. It
should be noted that nonhuman surveillance activities are
variable between jurisdictions. Another potential strategy
would be the development of a central notification system
that could alert transplant centers regarding regional WNV
activity.
A second option is to test during a defined period of time
that reflects the peak of WNV infection in most of the
United States (typically May 1 to November 1). This may be
simpler for centers to adopt. In addition, this reduces the
likelihood of communication error between laboratories and
blood banks. The major disadvantage with this method is
that potential donors will be tested despite the absence of
circulating WNV in their locales, thereby increasing the
likelihood of false-positive test results.
Any potential donor with a recent febrile illness should be
screened by local infectious diseases expertise prior to
donation. This screening may include West Nile testing as
appropriate.
During mosquito season, prospective live donors should be
counseled to use personal protective measures against
mosquito bites such as insect repellents and avoidance of
outside activities between dusk to dawn. These practices
are meant to mitigate the risk of acquiring WNV between
diagnostic testing and organ donation.
How should live donors be tested?
For laboratory screening, live donors should be screened by
WNVNATwithin 7–14 days of donation. There are currently
two FDA-licensed donor screening NAT assays utilized by
screening laboratories to detect the presence of infectious
WNVvirus (Table 4). TheProcleix1WNVAssay (Gen-probe;
Novartis Diagnostics, Basel, Switzerland) is based on
transcription-mediated amplification, a NAT, which tests
up to 16 specimens in the MP-NAT with a specificity of
99.95% and ID-NAT specificity of 99.89% (27,28). The
Cobas TaqScreen MPX test (Roche Molecular Diagnostics,
Branchburg, NJ) utilizes reverse transcription PCR (RT-
PCR) to test up to six specimens with an MP-NAT
specificity of 100% and ID-NAT specificity of 99.98%
(29,30) (Table 5). Interpretation of the results can be based
on the positive predictive value in each case, such as the
prevalence of WNV in the community where the donor
resides or has traveled.
The use of serologic testing offers an additional potential
strategy to screen potential living donors for WNV but
poses significant limitations in its performance and
interpretation. WNV antibody testing has been done to
establish the presence of past infection. This testing
involves (1) IgM, which develops within 2–3 days of
resolution of viremia, but may persist for >500 days (31),
and (2) IgG, which is identified within 2–3 days of IgM
production and persists for at least 5 years (32,33). It is
important to note that serologic tests against WNV are not
FDA licensed for the screening of donors. However, a
potential role for IgM antibody testing is raised by the
fact that two of the nine deceased organ donors who
Table 4: Performance summary of FDA-cleared WNV antibody diagnostic tests
Assay
Aggregate range of
specificity % (range 95% CI)
Aggregate range of clinical
sensitivity % (range 95% CI)
Focus Technologies WNV IgM Capture ELISA1 (39–41) 97.1–100 (92.7–100) 93.2–100 (81.3–100)
Focus Technologies WNV IgM Capture ELISA1 (42) 68–99.22 99.3
Focus Technologies WNV ELISA IgG (40,41,43) 90–98.8 (86–100)2 36–98.8 (25.2–99.9)2
Focus Technologies WNV ELISA IgG (42) 41–97.42 97.6
InBios WNV Detect IgM ELISA (44) 98.4–100 (94.3–100) 96.2–99.4 (87.0–99.9)
PANBIO WNV IgM Capture ELISA 3 (41,45) 85.5–98.4 (75–100) 76.7–100 (69–100)
PANBIO WNV IgG Indirect ELISA 3 (41,46) 88.1–92.6 (87.6–97.6) 76.3–99.3 (59.8–100)
Spectral Diagnostics WNV IgM STATus Test (47) 96–99.4 (82.8–99.9) 80–100 (59.3–100)
1Solely performance with background subtraction method reported.
2Excluded indeterminate samples in analysis.
3Not commercially available in the United States outside of research use.
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transmitted WNV and underwent screening prior to organ
procurement had negative RT-PCR assays but positive
WNV IgM and IgG antibodies (20–22,26). The failure of NAT
in one case was attributed to the decreased sensitivity of
the TaqMan RT-PCR (17). However, the second NAT failure
in a 2011 transmission case in California was reportedly
RT-PCR negative in serum and IgM positive as well (19).
Another major caveat of WNV antibody testing is the cross-
reactivity with other flaviviridae such as Dengue, Japanese
Encephalitis, St. Louis Encephalitis and Yellow fever among
others. Therefore, individuals who have had any of these
infections or vaccinations against flaviviridae may have
false-positive WNV antibody testing. Confirmatory testing
via plaque reduction neutralization assay may be obtained
through the CDC, although the results are generally not
available in a timely fashion to assist in donor screening
depending on the urgency of transplant.
Interpreting WNV testing
A positiveWNVNAT should lead to further evaluation of the
live donor and donation should be deferred until repeat
testing confirms resolution of viremia and infectivity. For
blood donors, the FDA recommends deferring donation for
120 days in those with confirmed WNV infection (32,34).
However, further management of a positive NAT test in live
donors is unclear because of limited data. One strategy
for donor testing is provided in Figure 1. It is reasonable to
repeat NAT testing in this situation; the time to repeat and
number of repeat samples may vary depending on the
Table 5: Performance summary of FDA-approved donor screening WNV NAT assays
Assay
Aggregate range
of specificity %
(range 95% CI)
Aggregate range
of clinical sensitivity %
(range 95% CI)
Aggregate 95%
limit of detection for
WNV RNA (95% CI)
Gen-Probe PROCLEIX
WNV Assay (28,48,49)
99.89–100 (99.89–100) 91.6–100 (86.9–100) 8.2–15 copies/mL (5.5–27.3)
Roche (14) Cobas TaqScreen
WNV Test (29,49,50)
99.986–100 (99.950–100) 100 (98.8–100) 40.3–125copies/mL or 0.8 plaque
forming units1 (17)
1Reference cites unpublished CDC data.
Figure 1: Strategy for testing live donors for West Nile virus.
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availability of the donor and turnaround time of testing. It is
unknown whether a negative NAT on repeat testing
confirms that the initial test was a false-positive result.
Failure to seroconvert at 28 days would lend support that
the initial NAT was false positive. Accordingly, a negative
repeat NAT andWNV IgM and IgG at 28 days suggests that
the original result was a false positive. Thus, transplantation
of the kidney from the donor could be considered at that
time. In contrast, a positive WNV IgM at 28 days in a donor
who previously had positive WNV NAT strongly suggests
that the donor had been infected, regardless of the repeat
NAT result; however, making clinical decisions based upon
a positive IgM result in this setting is not clear. While a
negative NAT and positive IgM at 28 days likely indicate
clearance of viremia and the development of protective
antibodies, the duration of WNV persistence in organs is
unknown. Therefore, the appropriate period to wait in a
donor with confirmed WNV infection is also unknown.
Clinical history together with seasonal and geographic
considerationsmay further assist in the risk assessment for
WNV transmission.
Posttransplant management of recipients of a
WNV-positive organ donor
At this time, there is no effective treatment for WNV.
Consequently, donorswith activeWNV should be deferred.
In the event of inadvertent transplantation from a WNV
infected donor, immunosuppression should be minimized
and hyperimmune globulin can be considered (35). Hyper-
immune globulin may be available on a compassionate use
basis fromOmrix andwould likely require an IND; however,
the presence of antibody to WNV in US-derived immune
globulin has been reported (19,36–38). Recipients may
be monitored with serial NAT testing to determine the
presence of infection. In the event of a positive NAT result,
consultation with local infectious diseases experts is
recommended, as well as reporting to transplant centers
and public health authorities.
Conclusions
Identifying live donors with potentially transmissible
infections should enhance the safety of transplantation, a
key objective of the OPTN in mandating testing for WNV,
T. cruzi and Strongyloides in this setting. Given that these
are uncommon infections in the United States, typically
occurring in individuals with specific epidemiologic risk
factors, broad testing of all donors throughout the year and
in all locales may not be cost-efficient and, in some cases,
may unnecessarily eliminate donors or delay transplanta-
tion due to false-positive results. In all cases, live donors
should also be notified of their positive results. Identifying
at-risk donors for targeted testing is critical for efficient
utilization of live donors. Banking serum may be a useful
tool for confirming donor-derived infection with Strong-
yloides, T. cruzi and WNV.
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